In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non- and Non- Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective Endocarditis.

(1) Background: Alternative antibiotics are needed to treat infective endocarditis (IE) caused by non-/non- enterococci; we aimed to assess the in vitro activity of ampicillin plus ceftriaxone (AMP + CTR) against these enterococci and to describe its clinical efficacy in IE cases. (2) Methods: Time-kill curves with standard (ISI) and high (IHI) inocula were performed to test isolates [3 (ECAS) and 1 (EGALL)] and non- isolates [1 (EDUR), 1 (EHIR) and 1 (ERAF)]. The narrative literature review of IE cases treated with AMP + CTR was analyzed alongside three study cases.

Systematic Coronary Risk Evaluation 2 for Older Persons (SCORE2-OP): 10 years risk validation, clinical utility and potential improvement.

Aims: European Systematic Coronary Risk Assessment 2 for Older Persons (SCORE2-OP) model has shown modest performance when externally validated in selected cohorts. We aim to investigate its predictive performance and clinical utility for 10-years cardiovascular (CV) risk in an unbiased and representative cohort of older people of a low CV risk country. Furthermore, we explore whether other clinical or echocardiographic features could improve its performance.

Costs during the first year after stroke by degree of functional disability: A societal perspective.

Introduction: The aim of this study was to estimate societal costs during the first year after stroke by degree of functional disability.

Patients And Methods: Descriptive study of the cumulative costs incurred during 1-year follow-up of a cohort of patients with stroke in Catalonia (Spain) participating in a multicentre, population-based, cluster-randomised trial (RACECAT). Patients were recruited between September 2017 and January 2019.

Diabetes Microvascular Complications Are Associated with a Reduction in Gait Speed in High-Functioning Older Adults for Outpatient Clinics.

Although the association of type 2 diabetes (T2D) with an increased risk of poor physical function and frailty in older adults is widely documented, the underlying pathophysiological pathways linking these two entities are not fully understood. Accordingly, we conducted a cross-sectional observational study aiming to investigate the association of T2D and its microvascular complications retinopathy, nephropathy, and neuropathy, with gait speed (GS), a common surrogate marker of functional decline, adjusting for age, sex, and cognitive function, in the cohort of older adults of the DIALCAT project (Catalonia, Spain). From the initial 335 participants, 84 were excluded because of missing or incorrect GS assessment.

Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy.

The highly prevalent metabolic dysfunction-associated steatohepatitis (MASH) is associated with liver steatosis, inflammation, and hepatocyte injury, which can lead to fibrosis and may progress to hepatocellular carcinoma and death. New treatment modalities such as gene therapy may be transformative for MASH patients. Here, we describe that one-time intramuscular administration of adeno-associated viral vectors of serotype 1 (AAV1) encoding native fibroblast growth factor 21 (FGF21), a key metabolic regulator, resulted in sustained increased circulating levels of the factor, which mediated long-term (>1 year) MASH and hepatic fibrosis reversion and halted development of liver tumors in obese male and female mouse models.